{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:12:37Z","timestamp":1792069957196,"version":"4.4.0"},"reference-count":70,"publisher":"The Endocrine Society","issue":"9","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"OGEDA SA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Polycystic ovary syndrome (PCOS), a highly prevalent endocrine disorder characterized by hyperandrogenism, is the leading cause of anovulatory infertility.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This proof-of-concept study evaluated clinical efficacy and safety of the neurokinin 3 (NK3) receptor antagonist fezolinetant in PCOS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a phase 2a, randomized, double-blind, placebo-controlled, multicenter study (EudraCT 2014-004409-34). The study was conducted at 5 European clinical centers. Women with PCOS participated in the study. Interventions included fezolinetant 60 or 180 mg\/day or placebo for 12 weeks. The primary efficacy end point was change in total testosterone. Gonadotropins, ovarian hormones, safety and tolerability were also assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy-three women were randomly assigned, and 64 participants completed the study. Adjusted mean (SE) changes in total testosterone from baseline to week 12 for fezolinetant 180 and 60 mg\/day were \u22120.80 (0.13) and \u22120.39 (0.12) nmol\/L vs \u22120.05 (0.10) nmol\/L with placebo (P\u2005&amp;lt;\u2005.001 and P\u2005&amp;lt;\u2005.05, respectively). Adjusted mean (SE) changes from baseline in luteinizing hormone (LH) for fezolinetant 180 and 60 mg\/d were \u221210.17 (1.28) and \u22128.21 (1.18) vs \u22123.16 (1.04) IU\/L with placebo (P\u2005&amp;lt;\u2005.001 and P\u2005=\u2005.002); corresponding changes in follicle-stimulating hormone (FSH) were \u22121.46 (0.32) and \u22120.92 (0.30) vs \u22120.57 (0.26) IU\/L (P\u2005=\u2005.03 and P\u2005=\u2005.38), underpinning a dose-dependent decrease in the LH-to-FSH ratio vs placebo (P\u2005&amp;lt;\u2005.001). Circulating levels of progesterone and estradiol did not change significantly vs placebo (P\u2005&amp;gt;\u2005.10). Fezolinetant was well tolerated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Fezolinetant had a sustained effect to suppress hyperandrogenism and reduce the LH-to-FSH ratio in women with PCOS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab320","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T21:01:40Z","timestamp":1621285300000},"page":"e3519-e3532","source":"Crossref","is-referenced-by-count":58,"title":["Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9182-5929","authenticated-orcid":false,"given":"Graeme L","family":"Fraser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[{"name":"Medical University, 8036 Graz,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop","family":"Laven","sequence":"additional","affiliation":[{"name":"Erasmus MC, 3015 Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0606-5804","authenticated-orcid":false,"given":"Georg","family":"Griesinger","sequence":"additional","affiliation":[{"name":"Schleswig-Holstein University Hospital, 23562 L\u00fcbeck,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axelle","family":"Pintiaux","sequence":"additional","affiliation":[{"name":"CHR Li\u00e8ge Citadelle Hospital, 4020 Li\u00e8ge,Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Timmerman","sequence":"additional","affiliation":[{"name":"University Hospital, KU Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-4371","authenticated-orcid":false,"given":"Bart C J M","family":"Fauser","sequence":"additional","affiliation":[{"name":"University Medical Center, 3584 Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lademacher","sequence":"additional","affiliation":[{"name":"Astellas Pharma US Inc, Northbrook, IL 60062,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Combalbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid R","family":"Hoveyda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ramael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"issue":"3","key":"2021120108561481600_CIT0001","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jfprhc-2012-100505","article-title":"A guide to understanding polycystic ovary syndrome (PCOS)","volume":"40","author":"Duncan","year":"2014","journal-title":"J Fam Plann Reprod Health Care."},{"issue":"12","key":"2021120108561481600_CIT0002","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod."},{"issue":"8","key":"2021120108561481600_CIT0003","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1210\/jc.2005-0628","article-title":"Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span","volume":"90","author":"Azziz","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"13","key":"2021120108561481600_CIT0004","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/archinternmed.2011.288","article-title":"Polycystic ovary syndrome in the United States: clinical visit rates, characteristics, and associated health care costs","volume":"171","author":"Jason","year":"2011","journal-title":"Arch Intern Med."},{"issue":"12","key":"2021120108561481600_CIT0005","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1210\/jc.2013-2350","article-title":"Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline","volume":"98","author":"Legro","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021120108561481600_CIT0006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","journal-title":"Hum Reprod."},{"issue":"1","key":"2021120108561481600_CIT0007","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.fertnstert.2016.05.003","article-title":"Criteria, prevalence, and phenotypes of polycystic ovary syndrome","volume":"106","author":"Lizneva","year":"2016","journal-title":"Fertil Steril."},{"issue":"4","key":"2021120108561481600_CIT0008","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/humrep\/dev010","article-title":"Symptom patterns and phenotypic subgrouping of women with polycystic ovary syndrome: association between endocrine characteristics and metabolic aberrations","volume":"30","author":"Huang","year":"2015","journal-title":"Hum Reprod."},{"issue":"6","key":"2021120108561481600_CIT0009","doi-asserted-by":"crossref","first-page":"e1003132","DOI":"10.1371\/journal.pmed.1003132","article-title":"Distinct subtypes of polycystic ovary syndrome with novel genetic associations: an unsupervised, phenotypic clustering analysis","volume":"17","author":"Dapas","year":"2020","journal-title":"PloS Med."},{"issue":"10","key":"2021120108561481600_CIT0010","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1210\/en.2019-00428","article-title":"Neuroendocrine impairments of polycystic ovary syndrome","volume":"160","author":"Ruddenklau","year":"2019","journal-title":"Endocrinology."},{"issue":"47","key":"2021120108561481600_CIT0011","doi-asserted-by":"crossref","first-page":"E10216","DOI":"10.1073\/pnas.1713897114","article-title":"Definition of the hypothalamic GnRH pulse generator in mice","volume":"114","author":"Clarkson","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"10","key":"2021120108561481600_CIT0012","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1210\/jc.2019-00146","article-title":"Hypothalamic reproductive endocrine pulse generator activity independent of neurokinin B and dynorphin signaling","volume":"104","author":"Lippincott","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"2021120108561481600_CIT0013","doi-asserted-by":"crossref","first-page":"100837","DOI":"10.1016\/j.yfrne.2020.100837","article-title":"A simple model of estrous cycle negative and positive feedback regulation of GnRH secretion","volume":"57","author":"Herbison","year":"2020","journal-title":"Front Neuroendocrinol."},{"issue":"4","key":"2021120108561481600_CIT0014","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1093\/humupd\/dml017","article-title":"The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome","volume":"12","author":"Blank","year":"2006","journal-title":"Hum Reprod Update."},{"issue":"1","key":"2021120108561481600_CIT0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1210\/jcem-66-1-165","article-title":"Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization","volume":"66","author":"Waldstreicher","year":"1988","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2021120108561481600_CIT0016","first-page":"2248","article-title":"Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome","volume":"82","author":"Taylor","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021120108561481600_CIT0017","first-page":"4179","article-title":"Resistance of gonadotropin releasing hormone drive to sex steroid-induced suppression in hyperandrogenic anovulation","volume":"82","author":"Daniels","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021120108561481600_CIT0018","first-page":"582","article-title":"Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone","volume":"83","author":"Pastor","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021120108561481600_CIT0019","first-page":"4047","article-title":"Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone","volume":"85","author":"Eagleson","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2021120108561481600_CIT0020","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/ncpendmet0637","article-title":"The reproductive phenotype in polycystic ovary syndrome","volume":"3","author":"Chang","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab."},{"key":"2021120108561481600_CIT0021","first-page":"104","article-title":"Polycystic ovary syndrome: current status and future perspective","volume":"6","author":"Barthelmess","year":"2014","journal-title":"Front Biosci (Elite Ed)."},{"key":"2021120108561481600_CIT0022","volume-title":"International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome 2018.","author":"Teede","year":"2018"},{"issue":"Pt B","key":"2021120108561481600_CIT0023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ddmod.2020.11.008","article-title":"The central role of ovulatory disturbances in the etiology of androgenic polycystic ovary syndrome (PCOS)\u2014evidence for treatment with cyclic progesterone","volume":"32","author":"Briden","year":"2020","journal-title":"Drug Discov Today Dis Models."},{"key":"2021120108561481600_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37559","article-title":"Epidemiology, diagnosis, and management of polycystic ovary syndrome","volume":"6","author":"Sirmans","year":"2013","journal-title":"Clin Epidemiol."},{"issue":"12","key":"2021120108561481600_CIT0025","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1210\/jc.2016-2132","article-title":"Interactions between neurokinin B and kisspeptin in mediating estrogen feedback in healthy women","volume":"101","author":"Skorupskaite","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021120108561481600_CIT0026","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/jc.2015-3621","article-title":"The NK3 receptor antagonist ESN364 suppresses sex hormones in men and women","volume":"101","author":"Fraser","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021120108561481600_CIT0027","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1210\/jc.2017-01306","article-title":"Neurokinin B regulates gonadotropin secretion, ovarian follicle growth, and the timing of ovulation in healthy women","volume":"103","author":"Skorupskaite","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021120108561481600_CIT0028","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1210\/jc.2016-1202","article-title":"Neurokinin B receptor antagonism in women with polycystic ovary syndrome: a randomized, placebo-controlled trial","volume":"101","author":"George","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021120108561481600_CIT0029","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/humrep\/deaa104","article-title":"Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome","volume":"35","author":"Skorupskaite","year":"2020","journal-title":"Hum Reprod."},{"issue":"3","key":"2021120108561481600_CIT0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-0039-3400241","article-title":"Neurokinin B and neurokinin-3 receptor signaling: promising developments in the management of menopausal hot flushes","volume":"37","author":"Modi","year":"2019","journal-title":"Semin Reprod Med."},{"issue":"7","key":"2021120108561481600_CIT0031","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1021\/acsmedchemlett.5b00117","article-title":"Optimization of novel antagonists to the neurokinin-3 receptor for the treatment of sex-hormone disorders (Part II)","volume":"6","author":"Hoveyda","year":"2015","journal-title":"ACS Med Chem Lett."},{"issue":"11","key":"2021120108561481600_CIT0032","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/en.2015-1409","article-title":"The NK3 receptor antagonist ESN364 interrupts pulsatile LH secretion and moderates levels of ovarian hormones throughout the menstrual cycle","volume":"156","author":"Fraser","year":"2015","journal-title":"Endocrinology."},{"issue":"12","key":"2021120108561481600_CIT0033","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1210\/jc.2019-00677","article-title":"Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial","volume":"104","author":"Depypere","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021120108561481600_CIT0034","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/GME.0000000000001510","article-title":"A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause","volume":"27","author":"Fraser","year":"2020","journal-title":"Menopause."},{"key":"2021120108561481600_CIT0035","volume-title":"Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO\/IDF Consultation.","author":"World Health Organization","year":"2006"},{"key":"2021120108561481600_CIT0036","volume-title":"Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Advanced Report of a WHO Consultation.","author":"World Health Organization","year":"2011"},{"issue":"6","key":"2021120108561481600_CIT0037","first-page":"1976","article-title":"Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS)","volume":"83","author":"Cronin","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2021120108561481600_CIT0038","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/humrep\/deh048","article-title":"The polycystic ovary syndrome health-related quality of life questionnaire (PCOSQ): a validation","volume":"19","author":"Jones","year":"2004","journal-title":"Hum Reprod."},{"key":"2021120108561481600_CIT0039","volume-title":"Validation of an LC\/MS-MS Method for the Determination of Testosterone in Lithium Heparinised Human Plasma [Validation Report No. B1121044].","author":"SGS Life Science Services","year":"2014"},{"issue":"12","key":"2021120108561481600_CIT0040","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry."},{"key":"2021120108561481600_CIT0041","volume-title":"The Columbia Scale (C-SSRS). A Unique Suicide Risk Assessment Tool: the Columbia Lighthouse Project.","year":"2016"},{"key":"2021120108561481600_CIT0042","volume-title":"Evaluation of the Menstrual Cycle and Timing of Ovulation.","author":"Welt","year":"2019"},{"issue":"11","key":"2021120108561481600_CIT0043","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1210\/en.2018-00653","article-title":"The gonadotropin-releasing hormone pulse generator","volume":"159","author":"Herbison","year":"2018","journal-title":"Endocrinology."},{"issue":"2","key":"2021120108561481600_CIT0044","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.yfrne.2012.02.002","article-title":"A comparison of the neuroendocrine mechanisms underlying the initiation of the preovulatory LH surge in the human, Old World monkey and rodent","volume":"33","author":"Plant","year":"2012","journal-title":"Front Neuroendocrinol."},{"issue":"12","key":"2021120108561481600_CIT0045","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1172\/JCI139681","article-title":"Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders","volume":"130","author":"Abbara","year":"2020","journal-title":"J Clin Invest."},{"issue":"52","key":"2021120108561481600_CIT0046","doi-asserted-by":"crossref","first-page":"13804","DOI":"10.1073\/pnas.1716097115","article-title":"Obligatory role of hypothalamic neuroestradiol during the estrogen-induced LH surge in female ovariectomized rhesus monkeys","volume":"114","author":"Kenealy","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2021120108561481600_CIT0047","article-title":"Physiology of GNRH and gonadotropin secretion","volume-title":"Endotext.","author":"Marques","year":"2018"},{"issue":"1","key":"2021120108561481600_CIT0048","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12020-018-1609-1","article-title":"Kisspeptin and LH pulsatile temporal coupling in PCOS patients","volume":"61","author":"Katulski","year":"2018","journal-title":"Endocrine."},{"issue":"6","key":"2021120108561481600_CIT0049","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1210\/jc.2002-022002","article-title":"Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism","volume":"88","author":"Ib\u00e1\u00f1ez","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021120108561481600_CIT0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.fertnstert.2004.05.098","article-title":"Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment","volume":"83","author":"Fleming","year":"2005","journal-title":"Fertil Steril."},{"issue":"4","key":"2021120108561481600_CIT0051","doi-asserted-by":"crossref","first-page":"e1762","DOI":"10.1210\/clinem\/dgaa059","article-title":"AMH is higher across the menstrual cycle in early postmenarchal girls than in ovulatory women","volume":"105","author":"Ortega","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2021120108561481600_CIT0052","doi-asserted-by":"crossref","first-page":"197","DOI":"10.5653\/cerm.2019.00374","article-title":"Inter-ovarian differences in ultrasound markers of ovarian size in women with polycystic ovary syndrome","volume":"46","author":"Chun","year":"2019","journal-title":"Clin Exp Reprod Med."},{"issue":"1","key":"2021120108561481600_CIT0053","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1210\/jc.2003-030932","article-title":"Anti-M\u00fcllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age","volume":"89","author":"Laven","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021120108561481600_CIT0054","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12902-020-00569-6","article-title":"Role of anti-M\u00fcllerian hormone and testosterone in follicular growth: a cross-sectional study","volume":"20","author":"Lv","year":"2020","journal-title":"BMC Endocr Disord."},{"key":"2021120108561481600_CIT0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jtbi.2014.07.020","article-title":"Bifurcation analysis of a menstrual cycle model reveals multiple mechanisms linking testosterone and classical PCOS","volume":"361","author":"Hendrix","year":"2014","journal-title":"J Theor Biol."},{"issue":"12","key":"2021120108561481600_CIT0056","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1172\/JCI2081","article-title":"Androgens stimulate early stages of follicular growth in the primate ovary","volume":"101","author":"Vendola","year":"1998","journal-title":"J Clin Invest."},{"issue":"5","key":"2021120108561481600_CIT0057","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/humrep\/deq019","article-title":"Concentrations of AMH and inhibin-B in relation to follicular diameter in normal human small antral follicles","volume":"25","author":"Andersen","year":"2010","journal-title":"Hum Reprod."},{"issue":"12","key":"2021120108561481600_CIT0058","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1210\/jc.2003-030727","article-title":"Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest","volume":"88","author":"Pigny","year":"2003","journal-title":"J Clin Endocrinol Metab."},{"issue":"5 Suppl","key":"2021120108561481600_CIT0059","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.fertnstert.2007.03.066","article-title":"M\u00fcllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture","volume":"89","author":"Grossman","year":"2008","journal-title":"Fertil Steril."},{"key":"2021120108561481600_CIT0060","doi-asserted-by":"crossref","first-page":"10055","DOI":"10.1038\/ncomms10055","article-title":"Novel role for anti-M\u00fcllerian hormone in the regulation of GnRH neuron excitability and hormone secretion","volume":"7","author":"Cimino","year":"2016","journal-title":"Nat Commun."},{"issue":"6","key":"2021120108561481600_CIT0061","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41591-018-0035-5","article-title":"Elevated prenatal anti-M\u00fcllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood","volume":"24","author":"Tata","year":"2018","journal-title":"Nat Med."},{"issue":"2","key":"2021120108561481600_CIT0062","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41591-020-0751-5","article-title":"Using human genetics to understand the disease impacts of testosterone in men and women","volume":"26","author":"Ruth","year":"2020","journal-title":"Nat Med."},{"issue":"3","key":"2021120108561481600_CIT0063","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1210\/en.2005-1029","article-title":"Androgens increase gonadotropin-releasing hormone neuron firing activity in females and interfere with progesterone negative feedback","volume":"147","author":"Pielecka","year":"2006","journal-title":"Endocrinology."},{"issue":"7","key":"2021120108561481600_CIT0064","doi-asserted-by":"crossref","first-page":"e99405","DOI":"10.1172\/jci.insight.99405","article-title":"Ontogeny and reversal of brain circuit abnormalities in a preclinical model of PCOS","volume":"3","author":"Silva","year":"2018","journal-title":"JCI Insight."},{"issue":"12","key":"2021120108561481600_CIT0065","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1093\/humrep\/deu247","article-title":"Expression of neurokinin B\/NK3 receptor and kisspeptin\/KISS1 receptor in human granulosa cells","volume":"29","author":"Garc\u00eda-Ortega","year":"2014","journal-title":"Hum Reprod."},{"issue":"9","key":"2021120108561481600_CIT0066","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1210\/en.2016-1354","article-title":"Neurokinin B exerts direct effects on the ovary to stimulate estradiol production","volume":"157","author":"Qi","year":"2016","journal-title":"Endocrinology."},{"issue":"1","key":"2021120108561481600_CIT0067","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10815-018-1338-7","article-title":"Altered expression of the kisspeptin\/KISS1R and neurokinin B\/NK3R systems in mural granulosa and cumulus cells of patients with polycystic ovarian syndrome","volume":"36","author":"Blasco","year":"2019","journal-title":"J Assist Reprod Genet."},{"issue":"4","key":"2021120108561481600_CIT0068","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.fertnstert.2020.05.006","article-title":"Female infertility is associated with an altered expression of the neurokinin B\/neurokinin B receptor and kisspeptin\/kisspeptin receptor systems in ovarian granulosa and cumulus cells","volume":"114","author":"Blasco","year":"2020","journal-title":"Fertil Steril."},{"issue":"4","key":"2021120108561481600_CIT0069","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/REP-15-0044","article-title":"Follicular hyperandrogenism downregulates aromatase in luteinized granulosa cells in polycystic ovary syndrome women","volume":"150","author":"Yang","year":"2015","journal-title":"Reproduction."},{"issue":"5","key":"2021120108561481600_CIT0070","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/humupd\/dmu012","article-title":"Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"20","author":"Barry","year":"2014","journal-title":"Hum Reprod Update."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab320\/38934764\/dgab320.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/9\/e3519\/41379016\/dgab320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/9\/e3519\/41379016\/dgab320.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T13:58:38Z","timestamp":1638367118000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/9\/e3519\/6277155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":70,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,5,17]]},"published-print":{"date-parts":[[2021,8,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab320","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,5,17]]}}}